Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Guan, Peiyong  [Clear All Filters]
Journal Article
Chen J, Zuo Z, Gao Y, Yao X, Guan P, Wang Y, Li Z, Liu Z, Hong JHan, Deng P, et al. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. Clin Epigenetics. 2023;15(1):19.
Chen J, Hong JHan, Huang Y, Liu S, Yin J, Deng P, Sun Y, Yu Z, Zeng X, Xiao R, et al. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. 2023;22(1):85.
Jiang X, Lim CZi Hui, Li Z, Lee PLeng, Yatim SMaryam JM, Guan P, Li J, Zhou J, Pan J, Chng W-J, et al. Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML). PLoS One. 2015;10(4):e0122983.
Hong JHan, Yong CHan, Heng HLee, Chan JYongsheng, Lau MChan, Chen J, Lee JYi, Lim AHerbert, Li Z, Guan P, et al. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies. Gut. 2023.
Yu Z, Deng P, Chen Y, Lin D, Liu S, Hong J, Guan P, Chen J, Zhong M-E, Chen J, et al. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer. Proc Natl Acad Sci U S A. 2024;121(6):e2304619121.
Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, Liu L, Yu Z, Huang Y, Xiong Z, et al. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022.
Liu S, Zou Q, Chen J-P, Yao X, Guan P, Liang W, Deng P, Lai X, Yin J, Chen J, et al. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. J Clin Invest. 2021.